YOLFTbeta
Krka, d. d.

Krka, d. d.

KRKG · VI · Healthcare / Drug Manufacturers - Specialty & Generic

249.50EUR+3.00 (+1.22%)

Price History

Full chart

Market Stats

Previous Close246.50
Open243.00
Day Range243.00 – 252.00
52-Week Range216.49 – 273.00
Volume0
Market Cap7.52B
P/E (TTM)18.06
Forward P/E0.00
EPS13.76
Dividend Yield3.68%
Beta0.45
50-Day Avg259.35
200-Day Avg254.91

About

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabolism, and other therapeutic areas, as well as analgesics, vitamins, minerals, and vasoprotectives. In addition, the company offers animal health products, including antiparasitics, antimicrobials, and other products. Further, it provides health resort and tourist services. The company was founded in 1954 and is based in Novo Mesto, Slovenia.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Jo?e Colaric
  • Employees13.30K
  • Headquarters?marje?ka cesta 6, Novo Mesto, Slovenia, 8501, Austria
  • Websitehttps://www.krka.biz

Leadership

  • Dr. Jo?e ColaricPresident of Management Board & CEO · b. 1955
  • Dr. Mateja Vrecer Ph.D.Director of Quality Management & Employee Representative Deputy President of the Supervisory Board · b. 1966
  • Dr. Ales Rotar Ph.D.Member of the Management Board and Director of Pharmaceutical R&D & Production · b. 1960
  • Mr. David BratozMember of the Management Board · b. 1976
  • Dr. Vinko Zupancic Ph.D.Director of API R&D, Production & Supply Chain and Member of the Management Board · b. 1971
  • Ms. Milena KastelicMember of the Mgt. Board, Worker Director & Deputy Dir. of Pharmaceutical Production · b. 1968
  • Magistrate Toma? Sever MScDty Director of Sales, Director of Region Central Europe & Ind Employee Rep Member of Super Board · b. 1967
  • Dr. Mari BozicEmployee Representative Supervisory Board Member & Assistant Head of Pharmaceutical Development · b. 1964
  • Uros OzboltDirector of Finance
  • Matej BaseljTechnical Director

Financials

Income Statement

Currency: EUR2022-12-312023-12-312024-12-312025-12-31
Total Revenue1.72B1.81B1.91B2.04B
Growth (%)-+5.18%+5.71%+6.89%
Cost of Revenue743.06M779.68M815.66M858.02M
Gross Profit974.39M1.03B1.09B1.18B
Gross Margin56.73%56.84%57.29%57.96%
Operating Expense593.04M632.77M670.79M717.07M
Operating Income381.35M393.94M423.09M465.93M
Operating Margin22.20%21.81%22.16%22.83%
EBITDA542.02M472.19M512.07M596.46M
EBITDA Margin31.56%26.14%26.82%29.22%
Net Income363.30M313.95M356.99M403.24M
Net Income Margin21.15%17.38%18.69%19.76%
R&D162.58M178.58M184.85M188.16M
R&D as % of Total Revenue9.47%9.89%9.68%9.22%
Interest Expense1.26M474.00K481.00K7.01M
Interest Expense % of Total Revenue0.07%0.03%0.03%0.34%

Balance Sheet

Currency: EUR2022-12-312023-12-312024-12-312025-12-31
Total Assets2.69B2.76B2.85B3.04B
Total Liabilities548.99M582.52M611.24M665.51M
Total Equity2.12B2.16B2.22B2.36B
Cash518.93M174.01M344.89M347.82M

Cash Flow

Currency: EUR2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow467.65M227.25M360.93M528.62M
Capital Expenditure94.73M139.21M115.35M98.35M
Free Cash Flow372.92M88.04M245.58M430.27M
Dividends Paid175.04M204.38M230.88M251.96M
FCF to OCF79.74%38.74%68.04%81.40%
Dividend Paid to FCF46.94%232.14%94.01%58.56%

Earnings

Report DateNov 12, 2026
EPS Estimate-
EPS Actual-
Surprise-
TimingAfter-hours

Key Statistics & Ratios

Market Cap7.52B
Enterprise Value6.73B
Trailing P/E18.06
Forward P/E0.00
Price / Sales3.56
Price / Book2.89
EPS13.76
Book Value86.19
Revenue (TTM)2.11B
Gross Profit (TTM)1.26B
EBITDA605.88M
Profit Margin19.78%
Operating Margin28.47%
Return on Equity16.24%
Return on Assets9.95%
Shares Outstanding30.28M
Shares Float21.00M
Beta0.45
Dividend Yield3.68%
Dividend Rate9.10
Payout Ratio0.00%

Dividends

20261×
9.10Jul 21, 2026